Contact Information
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE CM Trial) (Protocol Number: Eidos AG10 301)
Gender
Any
Age Group
Any